In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone-Reference-Cited by-同舟云学术

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

Published:2014-08-08 Issue:3 Volume:29 Page:705-714
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ocio E M,Fernández-Lázaro D,San-Segundo L,López-Corral L,Corchete L A,Gutiérrez N C,Garayoa M,Paíno T,García-Gómez A,Delgado M,Montero J C,Díaz-Rodríguez E,Mateos M V,Pandiella A,Couto S,Wang M,Bjorklund C C,San-Miguel J F

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014238.pdf

Reference42 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364: 1046–1060.

3. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525–542.

4. Mitsiades CS, Hideshima T, Chauhan D, McMillin DW, Klippel S, Laubach JP et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009; 46: 166–175.

5. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345–1350.

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Targeted protein degradation: from mechanisms to clinic;Nature Reviews Molecular Cell Biology;2024-04-29

3. Cereblon-Targeting Ligase Degraders in Myeloma;Hematology/Oncology Clinics of North America;2024-04

4. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?;Life;2023-11-20

5. SETDB1 induces lenalidomide resistance in multiple myeloma cells via epithelial‑mesenchymal transition and PI3K/AKT pathway activation;Experimental and Therapeutic Medicine;2023-04-21